Immunogen
Seite 7 von 10 Neuester Beitrag: 30.11.23 14:33 | ||||
Eröffnet am: | 08.11.13 09:35 | von: Chalifmann3 | Anzahl Beiträge: | 242 |
Neuester Beitrag: | 30.11.23 14:33 | von: warkla2 | Leser gesamt: | 87.750 |
Forum: | Hot-Stocks | Leser heute: | 40 | |
Bewertet mit: | ||||
Seite: < 1 | 1 | 2 | 3 | 4 | 5 | 6 | | 8 | 9 | ... > |
ImmunoGen, Inc. (IMGN) Pre-Market Trading
$13.79* 1.6913.97%
*Delayed - data as of 03/26/2018 04:16:07 - Find a broker to begin trading IMGN now Exchange:NASDAQ.
5,65 $* 0,51 9,92%
* Verzögert - Stand: 07.07.2014 17:58:26 - Finden Sie einen Broker, der jetzt mit dem Handel von IMGN beginnt
ImmunoGen: Phase 3 Study With Mirvetuximab Soravtansine Fails To Meet Endpoint
By RTTNews Staff Writer ✉ | Published: 3/1/2019 6:51 AM ET
ImmunoGen, Inc., (IMGN) announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRa)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival in either the entire study population or in the pre-specified subset of patients with high FRa expression.
"This study with mirvetuximab did not result in the outcome that we had hoped for in platinum-resistant patients. We will further assess the data from FORWARD I to determine potential next steps with a monotherapy approach. In parallel, we have generated encouraging data with mirvetuximab combination regimens and will evaluate our ongoing studies as an independent path forward to support a registration in ovarian cancer," said Mark Enyedy, ImmunoGen's CEO.
Phase 3 Studie verfehlt Endpunkte
https://www.thestreet.com/investing/earnings/...eet-endpoint-14883020
Wenn das gut läuft.
FDA empfiehlt/möchte neue Phase 3 Studie
https://seekingalpha.com/news/...nsine-nda-shares-5-percent-premarket
27. Juni 2019 um 6.30 Uhr EDT
Jetzt geht los anschnallen bitte!!!!